Souhaitez-vous accéder aux communiqués récents ?

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms...

Abaxx Technologies Inc. is pleased to announce that it has received conditional approval to list its common shares on the Toronto Stock Exchange (TSX).

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to...

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from...

– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion...

Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently  U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH...

Abaxx has appointed leading commodities economist and market strategist, Jeff Currie, as Executive Co-Chairman of Abaxx Markets.

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in...

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the...